The US Food and Drug Administration initiated a new phase in the battle against COVID-19 with the emergency use authorization of Pfizer Inc./BioNTech SE and Moderna, Inc. Omicron BA.4/BA.5 bivalent booster vaccines. At the same time, the agency ended authorization of the monovalent mRNA COVID-19 vaccines as booster doses for individuals 12 years of age and older.
Pfizer/BioNTech said its updated, bivalent vaccine, authorized for individuals 12 years of age and older, will be shipped immediately, following final quality control checks. It said it has the capacity to ship up to 15 million doses by 9 September
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?